Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA) remains a difficult complication to address due to its high mortality rate, lack of standard diagnostic criteria and limited therapeutic options. Underscoring this challenge is the complex pathophysiology involved and multiple contributing factors that converge on a final pathway involving widespread endothelial injury and complement activation. In addressing our current understanding of TA-TMA, we highlight the risk factors leading to endothelial damage and a pathophysiological cascade that ensues. We have also compared the different definition criteria and biomarkers that can enable early intervention in TA-TMA patients. Current first-line management includes discontinuation or alteration of the immunosuppressive regimen, treatment of co-existing infectious and GVHD, aggressive hypertension control and supportive therapy. We discuss current pharmacological therapies, including newer agents that target the complement cascade and nitric oxide pathways.
INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) has revolutionized the management of many malignant and non-malignant diseases, but its adoption is often limited by treatment-related morbidity and mortality. 1 Among the complications in transplant recipients, thrombotic microangiopathy (TMA) is one of the most difficult to identify and manage. Transplant-associated TMA (TA-TMA) is defined as a syndrome of microangiopathic hemolytic anemia, renal dysfunction and neurological symptoms. 2 Its occurrence after transplant depends on a variety of factors, including HLA mismatch, conditioning and immunosuppressive regimens, presence of GVHD and infectious complications. 3 Pathophysiologically, TA-TMA represents the 'final common pathway' resulting from endothelial injury and microthrombi formation, 4 most commonly affecting the kidneys, lungs and the gastrointestinal tract. 5 The incidence of TA-TMA varies widely, in part, due to the lack of standard diagnostic criteria. The reported incidence of TA-TMA following allogeneic transplant ranged from 0% to 64% with mortality as high as 100% of cases in a review of 35 published case series, though 28 different diagnostic criteria were used. 6, 7 There have been many efforts at standardizing the diagnostic criteria of TA-TMA, [7] [8] [9] which continues to evolve due to the lack of specific clinical and laboratory markers for diagnosing TA-TMA and the co-existence of confounding complications such as GVHD, which can mimic aspects of its manifestations.
Recently, researchers have cast some light on the possible roles of nitric oxide (NO) 10, 11 and complement system 12, 13 in the pathophysiology of TA-TMA. 14 There have been reports of successful use of NO donors 10 and complement blocking drugs [15] [16] [17] in the management of TA-TMA. In light of these recent research findings, we will discuss the pathophysiology and potential new markers of TA-TMA, followed by a comprehensive review of treatment options.
PATHOPHYSIOLOGY

Risk factors-'two-hit' hypothesis
Classic TMA includes thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). Other forms of TMA include atypical HUS, antiphospholipid antibody syndrome, malignant hypertension, disseminated intravascular coagulation and scleroderma renal crisis. The pathophysiology of TA-TMA differs substantially from that of idiopathic TTP as evidenced by normal levels of ADAMTS13 18 and a normal von Willebrand factor multimer pattern. 19 It has more resemblance to atypical HUS as suggested by growing evidence of the role of complement dysregulation in its pathophysiology. Endothelial injury is fundamental to the pathogenesis of TA-TMA ( Figure 1 ). Raised levels of plasma markers of endothelial injury, including thrombomodulin, plasminogen-activator inhibitor-1 and soluble intercellular adhesion molecule-1, and electron microscopic evidence supports the central role of endothelial injury. 19, 20 Initiation of endothelial injury can be portrayed as a 'two-hit' process consisting of generation of risk factors that create a procoagulant state and subsequent exposure to conditions that facilitate endothelial injury (Figure 2 ). During the preconditioning period and early aplastic phase post HSCT, multiple risk factors are present that make endothelium more procoagulant [21] [22] [23] (Table 1 ). This transformation of endothelium creates the breeding ground on which initiators of endothelial injury act and lead to TMA. [22] [23] [24] [25] [26] [27] [28] [29] During the recovery phase and beyond, the 'second hit' can be caused by one or more agents (Table 2) leading to endothelial injury and initiating the process of platelet aggregation and thrombus formation in microvessels. 27, [30] [31] [32] Propagation of endothelial damage According to the proposed model (Figure 1 ), events leading to TMA in post-HSCT patients can be broadly classified into three phases: initiation phase, progression phase, and hemolysis phase.
Once endothelial damage has occurred during the initiation phase, various molecular pathways such as the complement cascade have important roles in its progression. The progression phase ultimately leads to TMA-like picture. All three phases are occurring simultaneously in different temporal and spatial distributions along the endothelium.
Initiation phase
Calcineurin and mechanistic target of rapamycin inhibition. The first cases of TA-TMA were reported to have occurred after cyclosporine A use. Mechanisms responsible include direct endothelial injury, decreased prostacyclin and NO levels and increased thromboxane A2 and endothelin levels. 11, 33 Cyclosporine A and tacrolimus have also been implicated in causing TMA in solid organ transplant patients. 34 Sirolimus has been widely used in combination with calcineurin inhibitor (CNI) for the prevention or treatment of GVHD since 1989, and there is growing evidence that this combination is associated with a higher incidence of TMA. Two different theories have been put forth explaining this phenomenon: sirolimus tend to significantly elevate intrarenal concentration of CNI, 35 and decrease the levels of vascular endothelial growth factor (VEGF) leading to increased risk of TMA. 11, 32 Clinicians are often forced to discontinue one or both agents and shift to suboptimal regimens (such as mycophenolate mofetil, corticosteroids) for GVHD prophylaxis in the event of TMA.
Conditioning therapy. Conditioning therapy, especially high-dose chemotherapy, is associated with increased incidence of TA-TMA 36 due to direct injury to the endothelium.
Infections. Infections, including CMV and human herpesvirus-6, cause endothelial damage and may cause TMA after HSCT. 37 These are lymphotropic viruses and infect monocytes and T-lymphocytes, which result in release of tumor necrosis factor Figure 1 . Proposed model for events occurring during the pathophysiology of TA-TMA. The pathophysiology of TA-TMA can be divided into three phases. During the initiation phase, various factors (contained in boxes) lead to injury to endothelium through different mechanisms. During the progression phase, the endothelial damage is further aggravated by various promoters or lack of protection by NO and vascular endothelial growth factor (VEGF). Injured endothelium activates alternative complement pathway, which further damages the endothelium. If complement regulation is dysfunctional, it can lead to uncontrolled complement activation. During the outcome phase, there is platelet aggregation over the injured endothelium, which forms microthrombi. These microthrombi obstruct vascular lumen and also cause mechanical destruction of RBCs. These events lead to thrombotic microangiopathy in the patient. Ang2 = angiopoietin 2; APC = antigenpresenting cell; BMT = bone marrow transplant; CEC = circulating endothelial cells; CSA = cyclosporine A; DSA = donor-specific antibodies; EMP = endothelial microparticles; Hb = hemoglobin; IFN = interferon; IL = interleukin; PAI = plasminogen-activator inhibitor; PGI 2 = prostacyclin; RSA = recipient-specific antibodies; TM = thrombomodulin; TXA 2 = thromboxane A2; vWF = von Willebrand factor.
(TNF)-α, interleukin-1 and other cytokines, which further damage endothelium.
Graft-versus-host disease. GVHD after HSCT can contribute to the development of TMA by damaging endothelium through activating T-lymphocytes.
Role of classical complement pathway. Chemotherapy, viral infection and GVHD activate classical complement pathway through direct tissue injury. C4d deposits, which covalently bind to tissue and are a marker of classical complement pathway activation, can be detected in renal arterioles of patients diagnosed with TA-TMA. 12 Progression phase Role of endothelial microparticles. Disrupted endothelial membrane releases minute vesicles into the bloodstream and are known as endothelial microparticles, which are procoagulant in nature. 38 These microparticles induce platelet aggregation and promote microthrombi formation that predisposes to TMA. 39 Increased production of endothelial microparticles has been demonstrated in the setting of idiopathic TTP and acute GVHD.
39,40
Role of circulating endothelial cells. Circulating endothelial cells are a marker of small blood vessel injury in TMA. Erdbruegger et al. 41 demonstrated that therapeutic plasma exchange (TPE) decreased the levels of circulating endothelial cells in patients who improved after receiving TPE.
Role of NO and VEGF. NO and VEGF have a protective role against TA-TMA. 11, 42 Low levels of these factors have been shown to cause TMA-like lesions in mice, while increased VEGF levels at Day +15 is correlated with improved survival and fewer complications. 43 NO causes local vasodilation, protects against circulating cytokines (for example, TNF-α) and also inhibits release of von Willebrand factor and P-selectins by inhibiting exocytosis of Weibel-Palade bodies. 11 Excessive hemolysis releases free hemoglobin that can bind NO, rendering them ineffective and promoting further endothelial damage.
10
Role of alternative complement pathway. Injured endothelium exposes damage-associated molecular patterns, which activates C3 to initiate alternative pathway activity ( Figure 3 ). Under physiological conditions, circulating Factor H acts as a cofactor for Factor I and regulates complement activity by inhibiting C3 convertase. If the activity of Factor H is diminished, it can lead to uncontrolled alternative complement pathway activation. Activated complements cause diffuse damage to endothelium. Genetic polymorphisms or autoantibodies against Factor H can reduce Factor H activity in some patients. 13 Complement Factor H-related (CFHR) proteins are another class of regulators that need to be studied more rigorously. These proteins regulate C5 convertase activity, and deletions in CFHR protein-encoding genes can lead to dysregulated complement activation.
Complement dysregulation is already known to have a significant role in the pathogenesis of microangiopathic syndromes such as atypical HUS, Shiga-toxin-associated HUS, TTP and HELLP Syndrome. 44, 45 TA-TMA is histologically identical to atypical HUS. 46 Jodele et al. 47 identified a high prevalence of autoantibodies to Factor H and deletions in CFHR3 and CFHR 1 genes in HSCT recipients developing TMA. Another interesting observation was that all patients who were found to have autoantibodies against Factor H were negative for these autoantibodies before transplantation. 47 These findings indicate that complement dysregulation is a de novo process in post-transplant patients and has an important role in post-HSCT TMA. Future studies should aim at testing various complement-blocking agents in TA-TMA patients.
Hemolysis phase As endothelial injury worsens, platelets aggregate and microthrombi are formed. These microthrombi lead to consumptive thrombocytopenia, affected organ failure and intravascular hemolysis due to mechanical destruction of RBCs.
CLINICAL AND LABORATORY FEATURES
Post-HSCT TMA is a multisystem disorder usually presenting between 20 days and 100 days after transplantation. It most commonly affects the kidneys but can involve the lungs, gastrointestinal tract, brain and heart 5 ( Table 3) . Renal manifestations of TA-TMA include elevated creatinine, proteinuria and Figure 2 . Two-hit hypothesis. Normal endothelium becomes procoagulant endothelium due to several risk factors present during preconditioning and early phase of the post-HSCT period. Initiators of endothelial injury act on this procoagulant epithelium and lead to thrombotic microangiopathy.
hypertension, all of which can be observed in HSCT patients without TA-TMA. Therefore, diagnosis of renal TA-TMA needs careful repeated assessments by experienced clinicians. It is imperative to keep in mind that, on occasion, TA-TMA may not manifest through kidney disease and may present with features of other organ failures, such as pulmonary hypertension, diarrhea, vomiting, confusion, headache or polyserositis (refractory pericardial effusion, pleural effusion or ascites). A high degree of clinical suspicion is required to identify organ injury pattern in non-renal TA-TMA.
DIAGNOSIS
Diagnostic criteria
Several studies 5, [7] [8] [9] have constructed algorithms to assist in the diagnose of TA-TMA using various clinical and laboratory criteria (Table 4) . However, definitive diagnosis of TMA is made by tissue biopsy. Characteristic histopathological findings include thickened capillary walls, occluded vascular lumens by microthrombi and endothelial separation with swelling and necrosis. 4, 48 Although affected organ biopsy (usually renal biopsy is performed if any) in conjunction with other clinical and laboratory data can provide a more definitive diagnosis, it is an invasive procedure with a significant risk of bleeding especially in post-HSCT patients. 2 Cho et al. 7 emphasized the limitation of diagnostic criteria involving renal or neurological dysfunction, which is only found in 20-29% of patients. 27 To overcome this limitation, Cho et al. proposed the term 'probable TMA' to classify patients who fulfill all diagnostic criteria except renal or neurological dysfunction.
More recently, Jodele et al. 5 added elevated serum C5b-9 levels to the diagnostic criteria and used proteinuria and hypertension as markers of renal dysfunction. As some degree of thrombocytopenia and anemia is common after HSCT, careful evaluation is required to evaluate for de novo or otherwise unexplained fall in cell counts. Before a diagnosis of TMA can be made, it is important to rule out disseminated intravascular coagulation, TTP and Coombs-positive hemolytic anemia in post-HSCT patients. Normal coagulation studies, ADAMTS13 activity 410%, negative direct antiglobulin test and presence of other diagnostic features mentioned in Table 4 strongly suggest TA-TMA as the diagnosis.
Potential future markers In 2014, Jodele et al. 49 identified that proteinuria ⩾ 30 mg/dL, hypertension and elevated lactate dehydrogenase are the earliest markers of TMA in post-HSCT patients, occurring 10-14 days before the diagnosis of TMA is made. These may be better markers of renal dysfunction compared with serum creatinine, which typically remains normal until significant injury has occurred. Other potential markers such as thrombomodulin levels, calcium-dependent cysteine protease (Calpain) levels and cystatin C have been correlated with kidney injury, [50] [51] [52] but further studies are needed.
Poor prognostic factors Jodele et al. 53 recently reported that proteinuria ⩾ 30 mg/dL and elevated serum C5b-C9 levels (evidence of terminal complement activation) are associated with worse prognosis, with a survival rate of o20%. These patients with 'high-risk TMA' benefited more from complement-targeting therapy such as eculizumab. 17, 53 Other known poor prognostic factors 5, 17, 27, 32, 54, 55 are summarized in Table 5 .
TREATMENT First-line treatment First-line management of TA-TMA is limited to supportive therapy that includes withdrawal or minimization of medication insult to endothelium (refer to Tables 1 and 2), treatment of co-existing conditions such as infections and GVHD that may aggravate TMA and aggressive hypertension management. 56 Caution should Membrane attack Complex Figure 3 . Alternative complement pathway. Injury to endothelium exposes damage-associated molecular patterns (DAMPs). C3 binds to these DAMPs and are activated. Upon activation, C3 undergoes cleavage to form C3a, which being an anaphylatoxin recruits effector cells, and C3b, which deposits on the cell surface. C3b transforms into C3 convertase using Factor Bb, cleaved from Factor B using Factor D (FD), and amplification positive feedback loop. C3 convertase also generates C5 convertases by attaching C3b to itself. C5 convertase cleaves C5 into C5a, which is an anaphylatoxin similar to C3a, and C5b, which further assembles into membrane attack complex using C6-C9. Factor I (FI), a serine protease, cleaves C3b into iC3b with the help of cofactors such as Factor H (FH) and breaks the amplification loop. CFHR proteins regulate the activity of C5 convertase.
be exercised while changing immunosuppressive regimen for GVHD prophylaxis as GVHD flare would complicate TA-TMA management. Such decision should be based on careful analysis of risk-benefit ratio.
Therapeutic plasma exchange TPE, the mainstay treatment in TTP, is not as beneficial in TA-TMA. Various studies in the past 15 years have reported a highly variable response rate ranging from 27% to 80% and a high mortality rate ranging from 44% to 100%. 8, 17, 56 Many factors influence the effectiveness of TPE such as timing of intervention, presence of concomitant acute GVHD, presence of antibodies such as antiFactor H and donor-or recipient-specific antibodies. 41, 57, 58 TPE is an invasive procedure often requiring central venous access and exposure to blood products. It also carries significant risk of serious complications, such as infection, hemorrhage, thrombosis, pneumothorax, pericardial tamponade, hypoxia, hypotension, serum sickness and anaphylaxis. 59 However, early initiation of TPE can be beneficial for some patients by replacing dysfunctional complement regulators, removing anti-Factor H antibodies or inflammatory cytokines and by removing promoters of endothelial damage such as circulating endothelial cells, endothelial microparticles and circulating free hemoglobin (which binds to NO) released from damaged RBCs. 56, 60 Recently, Jodele et al. 61 proposed the use of TPE and rituximab in HSCT patients with documented Factor H autoantibodies. They also cautioned against premature discontinuation of TPE, as they found that it takes 2-3 weeks of daily TPE sessions to resolve TMA in post-HSCT patients. Even after resolution, therapy should be tapered over 3-4 weeks with close monitoring of TMA markers. 61 Despite the high mortality rate and risk of serious complications associated with use of TPE in TA-TMA patients, TPE can be considered in the following settings: (1) If documented evidence of Factor H autoantibodies are present, (2) If newer agents such as eculizumab cannot be given due to any reason or (3) if TPE can be initiated early, that is, within 2-3 weeks of TA-TMA diagnosis. The decision to start TPE should be after carefully considering the risk-to-benefit ratio.
Changing of immunosuppressive regimens Changing the immunosuppressive regimen is an important initial step in the management of TA-TMA. However, there has been no proven correlation between CNI levels and TMA. 2 Therefore, merely reducing the dose of cyclosporine or tacrolimus or switching from cyclosporine A to tacrolimus (or vice versa) may not be effective. 62 In contrast, replacing CNIs with alternative immunosuppressant is more beneficial. 8, 32, 63 Alternative agents for prophylaxis or treatment of GVHD include mycophenolate mofetil, corticosteroids or interleukin-2 receptor antagonists, such as daclizumab and basiliximab. 63, 64 Interleukin-2 receptor (CD25) antibodies Wolff et al. 64 described resolution of TMA in 9 out of the 13 patients with concomitant GVHD and TMA who were switched from a CNI to daclizumab. Both daclizumab and basiliximab have similar efficacy and adverse effects, though basiliximab is more convenient to administer. 65 Both of these interleukin-2 receptor antibodies have the potential to be excellent alternative to CNIs.
Newer agents
In search of more effective treatments, many agents have been tried over the past 15 years. Some agents such as eculizumab, rituximab and defibrotide have gained more popularity and showed promising results in several studies. Figure 4 illustrates the expected mechanism of action of these agents.
Eculizumab
Classical and alternative complement pathways have recently emerged as primary offenders in the pathophysiology of TA-TMA. With this realization, terminal complement inhibitors such as eculizumab, a C5 inhibitor, have come up as a promising new agent in these patients. Recently, several case reports and small studies have reported successful use of eculizumab in TA-TMA with resolution in 67-92% of the patients. 5, 16, 66 Owing to lack of a well-established dosing schedule, eculizumab dosing Abbreviations: CTN = Blood and Marrow Transplant Clinical Trials Network; Hb = hemoglobin; HPF = high-power field; IWG = European LeukemiaNet International Working Group; LDH = lactate dehydrogenase; NA = not applicable; TA-TMA = transplantation-associated thrombotic microangiopathy. Abbreviations: hpf = high-power field; LDH = lactate dehydrogenase; TMA = thrombotic microangiopathy.
Transplant-associated thrombotic microangiopathy J Khosla et al for atypical HUS (aHUS) have been used and CH50 level was used to titrate doses, maintaining adequately suppressed CH50 levels (o 10% of lower limit of normal). 16 Eculizumab therapy in TA-TMA has many challenges, including difficulty in achieving therapeutic levels in critically ill patients, longer periods of induction therapy needed in many patients, significant cost, increased susceptibility to encapsulated bacterial infections such as meningococcemia and limited availability in many countries. 16 These patients would benefit from antimicrobial prophylaxis during the period of complement blockade as they are unable to mount an effective response to vaccines given after bone marrow transplant. Furthering this idea, Jodele et al. 67 proposed the use of antimeningococcal prophylaxis from the start of eculizumab therapy until 8 weeks after completion of therapy or till CH50 returns to normal.
Compared with aHUS, eculizumab for TA-TMA typically requires a longer induction time with at least 4-6 weeks of therapy. Also, in contrast to aHUS, eculizumab can be discontinued after TMA resolution without disease relapse, and lifelong treatment is not required. It is recommended to use eculizumab as monotherapy-concurrent use of TPE would remove eculizumab from the blood as well as replenish C5 available for activation. Concurrent use of eculizumab and rituximab may affect rituximab activity as the latter medication depends in part on complement activity. 17 Defibrotide Defibrotide is a polydeoxyribonucleotide salt that blocks plasminogen-activator inhibitor-1 and attenuates the effects of TNF. 68 Defibrotide protects against endothelium damage by CNIs by its antithrombotic and thrombolytic effects. A multicenter retrospective study with 64 TA-TMA patients observed a 55% overall response rate with defibrotide either as monotherapy or in conjunction with other therapies, without any major adverse effects. 27 Rituximab Rituximab, an anti-CD20 monoclonal antibody, has been successfully used in TA-TMA therapy as a monotherapy or in combination with TPE or defibrotide. 69, 70 The primary mechanism of action of rituximab in TMA involves antibody depletion and immune regulation. 69, 71 If used in conjunction with TPE, rituximab should be administered immediately after daily TPE sessions. 5 
NO donors
Therapies that increase NO levels in blood include TPE, 10 defibrotide, 72 rituximab, 10 eicosapentaenoic acid, 73 statins, 74 transdermal isosorbide tape 75 and TNF-α inhibitors. 76 Other potential therapies Other therapies that in theory may be beneficial for TA-TMA include recombinant thrombomodulin, VEGF, erythropoietin, TNF-α inhibitors, prostacyclin analog and bosentan. 77, 78 A number of new complement-inhibiting agents are being extensively studied, with potential to revolutionize the therapy of TMA in transplant recipients in near future. Their mechanisms of action are illustrated in (Figure 5 ). OMS721 is currently in Protectors of endothelium Promoters of endothelial damage Figure 4 . Mechanisms of action of treatments used in TA-TMA patients. This illustration is divided into two parts. The upper half represents the various mechanisms in human body that promote endothelial damage and treatments, which act on different components of these promoters to lead to improvement in TMA patients. The lower half represents various mechanisms by which the endothelium tries to protect itself from further damage and treatments, which act by enhancing these protective factors. The most commonly used treatments include TPE, rituximab, defibrotide and, recently, eculizumab. Other pharmacological options have been tried in fewer studies and larger studies are needed to assess for their potential. Ang2 = angiopoietin 2; APC = antigen-presenting cell; CAM = cell adhesion molecules; CEC = circulating endothelial cell; DSA = donor-specific antibodies; EMP = endothelial microparticles; EPA = eicosapentaenoic acid; FH = Factor H; Hb = hemoglobin; IL = interleukin; MAC = membrane attack complex; PAI = plasminogen-activator inhibitor; PGI 2 = prostacyclin; RSA = recipient-specific antibodies; TF = tissue factor; VEGF = vascular endothelial growth factor; vWF = von Willebrand factor. phase 2 clinical trials in atypical HUS, TTP and TA-TMA (Clinical trial ID NCT02222545). TNT003 has shown potential in classical pathway-mediated diseases, such as cold agglutinin disease. 79 ACH-4471 is the first oral complement inhibitor with promising therapeutic results in in vitro models of diseases with excessive activation of alternate complement pathway such as paroxysmal nocturnal hematuria and aHUS. 80 New-generation Compstatin analogs such as Cp40 and PEG-Cp40 provide a more comprehensive and effective blockade compared with eculizumab as it also blocks C3-mediated hemolysis and opsonization. 81 LFG316, a fully human monoclonal antibody against C5, is in phase 2 clinical trial in patients with TA-TMA (Clinical trial ID NCT02763644). In a recently published case report, 82 Coversin (rEV576), a recombinant protein derived from the saliva of Ornithodros moubata tick and acts as C5 inhibitor, is found to be beneficial in TA-TMA resistant to eculizumab. CCX168 is an oral C5a receptor antagonist in a phase 2 clinical trial in patients with aHUS (Clinical trial ID NCT02464891) and holds promise as a potential replacement for corticosteroids due to blockade of inflammation caused by C5a. Additional studies are required to further understand the therapeutic potential of these agents.
Future of TA-TMA The future looks promising for patients who suffer from TA-TMA as we gain further insight into the pathophysiology of this disorder. New markers are being investigated to enable the early detection and facilitate the management of TA-TMA. Standard treatment regimens including more well-defined indications and schedule for TPE, rituximab and eculizumab should be established by studying larger cohorts of patients with TA-TMA. Additional studies of newer, highly promising agents with novel mechanisms of action will also be crucial in furthering our understanding of this disorder. Promote/Leads to Inhibits/Blocks CCX168 C5b MAC Figure 5 . Sites of action of novel complement inhibiting therapies. This is an illustration of sites of action of various upcoming complement inhibiting therapies, which are under trial in vitro or in vivo. Serpins are serine protease-2 inhibitors such as C1-inhibitor, Aprotinin and tissue factor pathway inhibitor of various complement pathways. They have been found to block classical and lectin pathway in vitro by inhibitor C1 or Mannan-binding lectin-associated serine protease-2 (MBL MASP-2). OMS721 is a human monoclonal antibody to MBL MASP-2. TNT003 is a mouse monoclonal antibody targeting classical pathway-specific serine protease C1s. Compstatin analogs are cyclic peptide and binds C3 preventing its cleavage and C3 convertase formation. ACH4471 is an inhibitor of Factor D (FD), which cleaves Factor B in alternative pathway. Eculizumab is a humanized monoclonal antibody against C5, thus blocking terminal complement pathway. LFG316 is a fully human monoclonal antibody against C5. Coversin is a recombinant protein that inhibits C5 complement. CCX168 is a C5a receptor antagonist.
